GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ULTA · Jan 30, 2016

Ulta Beauty, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-16-523101General Corporate
Capex intensity37thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

7.62% · OPTIONAL · VALID

Revenue growth20thOwn-history percentile · N=15
Evidence method

Yoy · gp.fundamentals.revenue

21.06% · CORE · VALID

Gross margin53thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.gross_margin

35.28% · CORE · VALID

Operating margin89thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.operating_margin

12.90% · CORE · VALID

SBC intensity11thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.40% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History62 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
10.40%
Current
7.62%
Delta
-2.77%
Growth Decreased
Previous
22.12%
Current
21.06%
Delta
-1.06%
Margin Decreased
Previous
36.85%
Current
35.28%
Delta
-1.58%
Profitability Increased
Previous
12.16%
Current
12.90%
Delta
0.74%
Sbc Intensity Increased
Previous
0.39%
Current
0.40%
Delta
0.01%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.